Delivery Order SPE2DB24D2010-SPE2DB25FAANT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $5,344.02 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for RINVOQ ER 30 mg tablets (30-count units). This firm fixed price contract, which represents a child award under a larger indefinite delivery vehicle, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. The award was competitively awarded without set-aside designation, reflecting...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order worth $6,942.03 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 MG TABLET UU 30S. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for delivering a wide range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract has no set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,602.94 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contractor, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a $19,152.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging). The contract was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a $15,876.35 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed price contract, with an ultimate completion date of July 21, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $10,858.62. This is a non-set-aside, competitively awarded delivery order that will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,845.80 to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-tablet units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location....
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAANTDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. This award is a child contract issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for military and veteran healthcare systems, supplying brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. The parent IDC functions as a global pharmaceutical support vehicle enabling flexible fulfillment of federal medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.1k | 7/29/25 |